Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite.
Saved in:
| Title: | Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite. |
|---|---|
| Authors: | Tu, Ya‐Ping1 (AUTHOR) yaping.tu@immunogen.com, Hanze, Eva2 (AUTHOR), Zhu, Fengying3 (AUTHOR), Lagraauw, H. Maxime4 (AUTHOR), Sloss, Callum M.5 (AUTHOR), Method, Michael6 (AUTHOR), Esteves, Brooke6 (AUTHOR), Westin, Eric H.6 (AUTHOR), Berkenblit, Anna6 (AUTHOR) |
| Source: | British Journal of Clinical Pharmacology. Feb2024, Vol. 90 Issue 2, p568-581. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
